<?xml version="1.0" encoding="UTF-8"?>
<p>As demonstrated for BEO, NanoBEO has proven analgesic efficacy both in the inflammatory pain models of the capsaicin (59.26% improvement over control, ** 
 <italic>p</italic> &lt; 0.01; 
 <xref ref-type="fig" rid="pharmaceutics-13-00379-f002">Figure 2</xref>) and the formalin test (59.78% improvement over control, ** 
 <italic>p</italic> &lt; 0.01; 
 <xref ref-type="fig" rid="pharmaceutics-13-00379-f003">Figure 3</xref>) and in the neuropathic pain model of the PSNL (58.76% improvement over control, ** 
 <italic>p</italic> &lt; 0.01; 
 <xref ref-type="fig" rid="pharmaceutics-13-00379-f004">Figure 4</xref>). In comparison with the empty NDS (control), NanoBEO was also effective in preventing 4-methyl-histamine-induced scratching behavior (
 <xref ref-type="fig" rid="pharmaceutics-13-00379-f005">Figure 5</xref>a,b). The effect of NanoBEO on itching is reported in a short movie within the 
 <xref ref-type="app" rid="app1-pharmaceutics-13-00379">Supplementary Materials</xref>.
</p>
